Study identifier:D0817R00074
ClinicalTrials.gov identifier:NCT06380738
EudraCT identifier:N/A
CTIS identifier:N/A
A prospective observational study to evaluate real-world clinical outcomes and characteristics of patients with mCRPC treated with olaparib + abiraterone
metastatic castration-resistant prostate cancer
N/A
No
-
Male
250
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
Merck Sharp & Dohme LLC
No locations available
Arms | Assigned Interventions |
---|